Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

AIMS: We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. MATERIALS & METHODS: MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjuste...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnan, Amrita, Nooka, Ajay K, Chari, Ajai, Garfall, Alfred L, Martin, Thomas G, Nair, Sandhya, Lin, Xiwu, Qi, Keqin, Londhe, Anil, Pei, Lixia, Ammann, Eric, Kobos, Rachel, Smit, Jennifer, Parekh, Trilok, Marshall, Alexander, Slavcev, Mary, Usmani, Saad Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402759/
https://www.ncbi.nlm.nih.gov/pubmed/37114426
http://dx.doi.org/10.57264/cer-2022-0186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402759/
https://www.ncbi.nlm.nih.gov/pubmed/37114426
http://dx.doi.org/10.57264/cer-2022-0186

Ejemplares similares